Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Alex, Yaroshinsky"'
Autor:
Emerson C. Perin, Kenneth M. Borow, Timothy D. Henry, Farrell O. Mendelsohn, Leslie W. Miller, Elizabeth Swiggum, Eric D. Adler, David H. Chang, R. David Fish, Alain Bouchard, Margaret Jenkins, Alex Yaroshinsky, Jack Hayes, Olga Rutman, Christopher W. James, Eric Rose, Silviu Itescu, Barry Greenberg
Publikováno v:
Journal of the American College of Cardiology. 81:849-863
Autor:
Hee Jin Kim, Grace Kimmel, Jennifer Bares, Soo Jung Kim, Giselle Singer, Alex Yaroshinsky, Margot Chima, Mark Lebwohl, Jerry Bagel
Publikováno v:
SKIN The Journal of Cutaneous Medicine. 5:524-529
Background: Brodalumab is an interleukin-17 receptor A antagonist approved for the treatment of moderate-to-severe plaque psoriasis. Our prior publication reported significant disease improvement with brodalumab in psoriasis patients who had previous
Autor:
Sean Oosterholt, Oscar Della Pasqua, Tiago Gomes, Stuart Evans, Mike Snape, Hanns Lochmüller, Nikoletta Nikolenko, Joseph P. Horrigan, Alison McMorn, Alex Yaroshinsky
Publikováno v:
Pediatric Neurology. 112:84-93
GSK3β is an intracellular regulatory kinase that is dysregulated in multiple tissues in type 1 myotonic dystrophy, a rare neuromuscular disorder that manifests at any age. AMO-02 (tideglusib) inhibits GSK3β activity in preclinical models of type 1
Autor:
Pearl Grimes, Jag Bhawan, Michael Howell, Seemal Desai, Edna Coryell, Michael Einziger, Ann Simpson, Alex Yaroshinsky, Tim McCraw
Publikováno v:
Journal of drugs in dermatology : JDD. 21(2)
Malassezin is a natural indole compound produced by the fungus Malassezia furfur and preclinical investigations have demonstrated an ability to suppress melanogenesis.To investigate the histopathological effects of malassezin for treatment of facial
Autor:
Seemal R. Desai, Ann Marie Simpson, Alex Yaroshinsky, Jag Bhawan, Michael Einziger, Michael D. Howell, Tim McCraw, Pearl E. Grimes, Rama Nashawati, Edna Coryell
Publikováno v:
Journal of the American Academy of Dermatology. 87(2)
Publikováno v:
Circulation Research. 125:265-281
Advanced heart failure (HF) is a progressive disease characterized by recurrent hospitalizations and high risk of mortality. Indeed, outcomes in late stages of HF approximate those seen in patients with various aggressive malignancies. Clinical trial
Autor:
Elizabeth Berry-Kravis, Joseph P. Horrigan, Nicole Tartaglia, Randi Hagerman, Alexander Kolevzon, Craig A. Erickson, Shivkumar Hatti, Mike Snape, Alex Yaroshinsky, George Stoms, Larry Glass, Nancy E. Jones, Kevin Sanders, Jean Frazier, Thomas Challman, Jeffrey Innis, Bryan King, Joseph Cubells, Jeannie Visootsak, Steven Skinner, Dianne Treadwell-Deering, Sherry Sellers Vinson, Howard Needelman
Publikováno v:
Pediatric neurology. 110
We analyze the safety and tolerability of trofinetide and provide a preliminary evaluation of its efficacy in adolescent and adult males with fragile X syndrome.This study was an exploratory, phase 2, multicenter, double-blind, placebo-controlled, pa
Publikováno v:
Statistics in Medicine
This paper considers the analysis of a repeat event outcome in clinical trials of chronic diseases in the context of dependent censoring (e.g. mortality). It has particular application in the context of recurrent heart failure hospitalisations in tri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4d69cabf72ae3fe3665055433d5df41
https://ora.ox.ac.uk/objects/uuid:e6873d7c-bbde-49bc-aaeb-9e93a88ef54f
https://ora.ox.ac.uk/objects/uuid:e6873d7c-bbde-49bc-aaeb-9e93a88ef54f
Publikováno v:
Circulation research. 125(3)
Advanced heart failure (HF) is a progressive disease characterized by recurrent hospitalizations and high risk of mortality. Indeed, outcomes in late stages of HF approximate those seen in patients with various aggressive malignancies. Clinical trial
Autor:
David H, McDaniel, Jacob M, Waugh, Lily I, Jiang, Thomas J, Stephens, Alex, Yaroshinsky, Chris, Mazur, Mitchell, Wortzman, Diane B, Nelson
Objectives: Investigators sought to evaluate the antioxidant capacity of a comprehensive topical antioxidant (WEL-DS), its ability to protect skin against the oxidizing effects of UVA/UVB radiation, and to assess the effectiveness and tolerability of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::c07c834e979782e8aaa3fef984bc3588
https://europepmc.org/articles/PMC6508483/
https://europepmc.org/articles/PMC6508483/